SignaBlok wins NCI / NIH SBIR Phase II grant to test first-in-class TREM-1 inhibitor in combination with chemo- and immunotherapy for treatment of pancreatic cancer

SignaBlok > News > SignaBlok wins NCI / NIH SBIR Phase II grant to test first-in-class TREM-1 inhibitor in combination with chemo- and immunotherapy for treatment of pancreatic cancer

SignaBlok wins NCI / NIH SBIR Phase II grant to test first-in-class TREM-1 inhibitor in combination with chemo- and immunotherapy for treatment of pancreatic cancer

Vera

View posts by Vera
Scroll to top